Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Associação Médica Brasileira (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300318 |
Resumo: | SUMMARY OBJECTIVE: In coronavirus disease 2019, a rapidly progressive inflammatory process is considered to be the main cause of organ damage and mortality. Therefore, the importance of anti-inflammatory treatments such as tocilizumab is increasing. METHODS: A total of 107 patients who received tocilizumab between March 2020 and March 2021 were included in the study. The primary termination point was mortality. We compared surviving and deceased patients by the stage of the disease and where the drug was given (service or intensive care unit). RESULTS: The mean age was 60.8±14.6 years (minimum 29 years, maximum 96 years). According to the WHO staging system, 16 (15%) patients had moderate, 47 (43.9%) patients had severe, 44 (41.1%) patients had a critical illness. Although all patients were admitted to the service, 26 (24.3%) patients received tocilizumab in the intensive care unit. Of 107 patients, 80 (74.7%) survived and 27 (25.2%) died. Mortality was found to be significantly higher in critical patients (96.3%), severe patients (3.7%), and moderate patients (0%) (p<0.001). Peripheral oxygen saturation measured at admission was found to be significantly lower in patients who died. The initial saturations (p=0.008) were found to have independent effects on mortality. CONCLUSION: The results showed that tocilizumab is an effective treatment option for coronavirus disease 2019 disease and reduces mortality, but the key point is timing. |
id |
AMB-1_7712a8b97d146a6e1879f2e6181af583 |
---|---|
oai_identifier_str |
oai:scielo:S0104-42302022000300318 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timingTocilizumabEarly treatmentMortalityPeripheral oxygen saturation monitoringSUMMARY OBJECTIVE: In coronavirus disease 2019, a rapidly progressive inflammatory process is considered to be the main cause of organ damage and mortality. Therefore, the importance of anti-inflammatory treatments such as tocilizumab is increasing. METHODS: A total of 107 patients who received tocilizumab between March 2020 and March 2021 were included in the study. The primary termination point was mortality. We compared surviving and deceased patients by the stage of the disease and where the drug was given (service or intensive care unit). RESULTS: The mean age was 60.8±14.6 years (minimum 29 years, maximum 96 years). According to the WHO staging system, 16 (15%) patients had moderate, 47 (43.9%) patients had severe, 44 (41.1%) patients had a critical illness. Although all patients were admitted to the service, 26 (24.3%) patients received tocilizumab in the intensive care unit. Of 107 patients, 80 (74.7%) survived and 27 (25.2%) died. Mortality was found to be significantly higher in critical patients (96.3%), severe patients (3.7%), and moderate patients (0%) (p<0.001). Peripheral oxygen saturation measured at admission was found to be significantly lower in patients who died. The initial saturations (p=0.008) were found to have independent effects on mortality. CONCLUSION: The results showed that tocilizumab is an effective treatment option for coronavirus disease 2019 disease and reduces mortality, but the key point is timing.Associação Médica Brasileira2022-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300318Revista da Associação Médica Brasileira v.68 n.3 2022reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20210602info:eu-repo/semantics/openAccessGülhan,MuhammetÖnal,UğurDemirci,NeşeCetin,GulcanCalisir,AbdullahKöksalan,DamlaSolmaz,KübraKars,AyhanKilinc,CetinGülten,Sedateng2022-09-01T00:00:00Zoai:scielo:S0104-42302022000300318Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2022-09-01T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing |
title |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing |
spellingShingle |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing Gülhan,Muhammet Tocilizumab Early treatment Mortality Peripheral oxygen saturation monitoring |
title_short |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing |
title_full |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing |
title_fullStr |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing |
title_full_unstemmed |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing |
title_sort |
Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing |
author |
Gülhan,Muhammet |
author_facet |
Gülhan,Muhammet Önal,Uğur Demirci,Neşe Cetin,Gulcan Calisir,Abdullah Köksalan,Damla Solmaz,Kübra Kars,Ayhan Kilinc,Cetin Gülten,Sedat |
author_role |
author |
author2 |
Önal,Uğur Demirci,Neşe Cetin,Gulcan Calisir,Abdullah Köksalan,Damla Solmaz,Kübra Kars,Ayhan Kilinc,Cetin Gülten,Sedat |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Gülhan,Muhammet Önal,Uğur Demirci,Neşe Cetin,Gulcan Calisir,Abdullah Köksalan,Damla Solmaz,Kübra Kars,Ayhan Kilinc,Cetin Gülten,Sedat |
dc.subject.por.fl_str_mv |
Tocilizumab Early treatment Mortality Peripheral oxygen saturation monitoring |
topic |
Tocilizumab Early treatment Mortality Peripheral oxygen saturation monitoring |
description |
SUMMARY OBJECTIVE: In coronavirus disease 2019, a rapidly progressive inflammatory process is considered to be the main cause of organ damage and mortality. Therefore, the importance of anti-inflammatory treatments such as tocilizumab is increasing. METHODS: A total of 107 patients who received tocilizumab between March 2020 and March 2021 were included in the study. The primary termination point was mortality. We compared surviving and deceased patients by the stage of the disease and where the drug was given (service or intensive care unit). RESULTS: The mean age was 60.8±14.6 years (minimum 29 years, maximum 96 years). According to the WHO staging system, 16 (15%) patients had moderate, 47 (43.9%) patients had severe, 44 (41.1%) patients had a critical illness. Although all patients were admitted to the service, 26 (24.3%) patients received tocilizumab in the intensive care unit. Of 107 patients, 80 (74.7%) survived and 27 (25.2%) died. Mortality was found to be significantly higher in critical patients (96.3%), severe patients (3.7%), and moderate patients (0%) (p<0.001). Peripheral oxygen saturation measured at admission was found to be significantly lower in patients who died. The initial saturations (p=0.008) were found to have independent effects on mortality. CONCLUSION: The results showed that tocilizumab is an effective treatment option for coronavirus disease 2019 disease and reduces mortality, but the key point is timing. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300318 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300318 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1806-9282.20210602 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.68 n.3 2022 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212837359616000 |